Powered by the cutting-edge SAILINGTM multi-specific antibody optimization platform, the SparX bifunctional ADC (bi-ADC) technology dials-in an improved specificity, sensitivity, internalizing capability and trafficking to the lysosome to our drug candidates, enabling the development of next generation of antibody-drug conjugates. The SparX bi-ADC technology takes advantage of the multifunctional nature of bispecific antibodies to optimize specificity and more effectively target the tumor-killing ability of antibody-drug conjugates (ADCs).
ADCs are carefully designed conjugates of a chemical entity, particularly cytotoxic agents, via a molecular linker to a monoclonal antibody. Antibody-drug conjugates (ADC) utilize the specificity of monoclonal antibodies (mAbs) to selectively deliver small molecular drugs to antigen-expressing tumor cells. While the design concept is simple, the success of ADC depends on careful optimization of each building block including antibody, cytotoxic agent, linker and method of conjugation. In addition to the biological considerations, the heterogenous and biochemically complex nature of the conjugates presents challenges to the production and characterization of ADCs as therapeutic entities.
At SparX, we are driving innovations in the next-generation ADC, utilizing innovative multi-specific antibody discovery, site-specific conjugation using customized glycan remodeling and Q-tag bioconjugation, and protease or caspase-sensitive peptide linkers. The beauty of the SparX bi-ADC technology incudes customized target selectivity and sensitivity, which optimizes the ability of the ADC to internalize, selectively release payload in lysosomes also enabling a bystander cytotoxic effect. These strategies are enabled by site-specific conjugation for improved ADC manufacturability.
